1. Burns DM. Nicotine addiction. In: Wiener CM, Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Harrison’s principles of internal medicine. 19th ed. New York (NY): McGraw-Hill; 2005. p. 2729–32. 3. Korea Centers for Disease Control and Prevention. The Sixth Korea National Health and Nutrition Examination Survey (KNHANES VI-2), 2014 [Internet]. Cheongju, Korea Centers for Disease Control and Prevention. c2014;[cited 2018 Jun 22]. Available from: http://cdc.go.kr. 5. Paek YJ, Choi JK, Lee ES, Jo MW. Smoking cessation services provided by the National Health Insurance Service. J Korean Med Assoc 2018;61:157–62.

6. Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addict Behav 2004;29:51–60.

7. Celik I, Yuce D, Hayran M, Erman M, Kilickap S, Buzgan T, et al. Nationwide Smoking Cessation Treatment Support Program: Turkey project. Health Policy 2015;119:50–6.

8. Land T, Warner D, Paskowsky M, Cammaerts A, Wetherell L, Kaufmann R, et al. Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in smoking prevalence. PLoS One 2010;5:e9770.

9. Kumiko S, Tomotaka S, Masakazu N, Akira O, Keiji W, Nobuyuki H, et al. Smoking prevalence and beliefs on smoking cessation among members of the Japanese Cancer Association in 2006 and 2010. Cancer Sci 2012;103:1595–9.

10. Tait RJ, Hulse GK, Waterreus A, Flicker L, Lautenschlager NT, Jamrozik K, et al. Effectiveness of a smoking cessation intervention in older adults. Addiction 2007;102:148–55.

11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.

12. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040–56.

13. Lee JH, Jones PG, Bybee K, O’Keefe JH. A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol 2008;11:210–4.

14. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31:463–91.

15. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2015;(3): CD006936.

16. Park SS, Lee JY, Cho SI. Validity of expired carbon monoxide and urine cotinine using dipstick method to assess smoking status. J Prev Med Public Health 2007;40:297–304.